Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Incyte (INCY) insider activity: The company’s EVP & General Counsel reported a same‑day option exercise and sale on 11/04/2025. He exercised 598 employee stock options at $58.06 per share and sold 598 common shares at $101.36 per share.
Following these transactions, he directly owned 26,569 common shares. He also held 13,765 derivative securities (employee stock options) after the activity. In addition, the filing notes 25,913 shares of common stock are issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.
Incyte Corp (INCY) reported an insider transaction on Form 4. The company’s EVP, Head of Incyte Intl, sold 3,074 shares of common stock on 11/03/2025 at $94.02 per share.
Following the sale, the reporting person beneficially owned 29,241 shares directly. This figure includes 26,167 shares issuable pursuant to previously reported RSUs that have not vested.
Incyte reported stronger Q3 results, with total revenue of $1.366 billion, up from $1.138 billion a year ago. Net income rose to $424.2 million (diluted EPS $2.11) from $106.5 million ($0.54). Year to date, revenue reached $3.634 billion and net income was $987.4 million, a sharp improvement from a loss in the prior year.
Growth was broad-based: JAKAFI revenue was $791.1 million, OPZELURA $188.0 million, and new contributions included NIKTIMVO at $45.8 million and ZYNYZ at $22.7 million. Royalty revenue increased to $171.1 million, led by JAKAVI royalties of $125.6 million. Milestone and contract revenue was $45.0 million.
Operating expense trends were favorable. R&D for the quarter was $506.6 million versus $573.2 million, and cost of product revenues was $99.0 million. For the nine months, results also reflect a $242.3 million contract dispute settlement benefit tied to resolved JAKAFI royalties with Novartis and a 50% reduction in the ongoing U.S. JAKAFI royalty rate starting January 1, 2025. Cash and cash equivalents were $2.455 billion, with marketable securities of $474.8 million. Shares outstanding were 196,322,703 as of October 21, 2025.
Incyte Corporation filed a current report stating that it has released financial results for its third fiscal quarter ended September 30, 2025. The company furnished the full text of its earnings press release as Exhibit 99.1, dated October 28, 2025. The report is presented as routine financial disclosure under the item covering results of operations and financial condition.
Incyte (INCY) reported an insider transaction by its EVP & General Counsel. On 10/15/2025, the officer exercised 277 employee stock options at a $64.25 exercise price and sold 277 shares of common stock at $85.13.
Following the transactions, the officer beneficially owned 26,569 shares directly, which includes an aggregate of 25,913 shares issuable from previously reported unvested RSUs and earned performance units. Derivative securities beneficially owned after the transactions totaled 9,161 options. The reported option grant expires on 07/14/2034 and vests in installments as disclosed.
Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), reported multiple transactions on 10/02/2025 and 10/03/2025. She exercised employee stock options for 599 shares at an exercise price of $58.06 and acquired 599 common shares via that exercise. Concurrently, she sold a series of shares: 599 at $87.65, 3,130 at $86.28, and 3,501 at $85.54, reducing her direct common stock holdings to 26,569 shares. The filing notes 3,130 shares were withheld to satisfy tax obligations and that 25,913 shares remain issuable under previously reported restricted stock units and earned performance units that have not vested. After the reported activity, she holds 14,363 option-based derivative securities and 26,569 direct common shares.
Incyte Corporation (INCY) submitted a Form 144 notifying a proposed sale of 3,501 restricted shares valued at $299,464.34, to be executed through Morgan Stanley Smith Barney LLC on 10/03/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 10/02/2025 and the filer reports 195,276,145 shares outstanding for the issuer.
The filing lists prior insider sales by Sheila Denton over the past three months totaling 6,165 shares across seven transactions, with gross proceeds shown for each sale (largest single prior sale: 3,330 shares for $232,633.80 on 07/15/2025). The notice includes the standard signature representation that the seller has no undisclosed material adverse information and names the executing broker and address.
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), reported a disposition of company shares on 10/01/2025. The filing shows 1,569 shares of common stock were disposed of at a price of $86.70 per share under transaction code F, and the reporting person remains the beneficial owner of 65,819 shares following the transaction. The filing explains the 1,569 shares represent shares withheld automatically by the issuer to satisfy tax-withholding obligations associated with the settlement of previously reported restricted stock units.
The report also notes that of the remaining position, 59,858 shares are issuable pursuant to previously reported restricted stock units that have not vested. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.
Heeson Lee, EVP and Head of Incyte International, filed a Form 4 reporting changes in beneficial ownership of INCY common stock. On 10/01/2025 the filing shows 463 shares were disposed of (reported under Code F) at a price of $86.7 per share to satisfy tax withholding obligations tied to previously granted restricted stock units. After the reported transaction the filing shows beneficial ownership of 32,315 shares; the filer discloses that this total includes 26,167 shares issuable under previously reported unvested RSUs. The form is signed by an attorney-in-fact on 10/03/2025.
Incyte Corporation reported a leadership change in its finance organization. The Board of Directors appointed Thomas Tray, currently Vice President, Finance and Chief Accounting Officer, to also serve as the company’s principal financial officer, effective as of September 16, 2025.
Tray, age 48, has been with Incyte since 2005, starting as Manager of External Reporting and later serving as Vice President and Controller before his current roles. He holds a B.S. in Accounting from Mount Saint Mary’s University and an Executive MBA in Pharmaceutical Marketing from Saint Joseph’s University. The company states there are no special arrangements related to his appointment, no family relationships with directors or executive officers, and no material related-party transactions requiring disclosure.